ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16; US commercial launch initiatedBLA approval triggers $30m milestone payment to Autolus ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

This, they concluded, indicates a shared founder clone of chronic and blast phases with different driver mutations and therefore different progressing capacities. This finding was further supported by ...

Acute lymphoblastic leukemia (ALL) is a form of leukemia, or cancer of the white blood cells characterized by ... in a relatively immature (also termed 'blast') state. Science X Daily and the ...

Rong Lu, associate professor of stem cell biology and regenerative medicine, biomedical engineering, medicine, and gerontology at USC, and a Leukemia & Lymphoma Society Scholar Lu is also a member of ...

Former Hollywood producer Harvey Weinstein has chronic myeloid leukemia (CML), NBC News reported on Monday, citing sources. Weinstein is currently undergoing treatment for CML, a type of bone ...

It is a slow-growing type of leukemia that can turn acute if not treated quickly with targeted therapy, according to the American Cancer Society. Because CML is not as common as other blood ...